+

WO2018106928A1 - Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3 - Google Patents

Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3 Download PDF

Info

Publication number
WO2018106928A1
WO2018106928A1 PCT/US2017/065132 US2017065132W WO2018106928A1 WO 2018106928 A1 WO2018106928 A1 WO 2018106928A1 US 2017065132 W US2017065132 W US 2017065132W WO 2018106928 A1 WO2018106928 A1 WO 2018106928A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
substituted
group
saturated
carbon chain
Prior art date
Application number
PCT/US2017/065132
Other languages
English (en)
Inventor
Robert Thomas FOSTER
Philippe Gallay
Daniel Joseph TREPANIER
Daren Raymond URE
Original Assignee
Contravir Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Contravir Pharmaceuticals, Inc. filed Critical Contravir Pharmaceuticals, Inc.
Publication of WO2018106928A1 publication Critical patent/WO2018106928A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Definitions

  • Cyclosporines are a class of cyclic polypeptides having potent immunosuppressant activity. Among the many compounds in the cyclosporine family, Cyclosporine A (CsA) is the most widely used medically. Cyclosporines have three well established targets: calcineurin, the CyP isoforms (e.g., CyP-A, CyP-B, and CyP-D), and P-glycoprotein (PgP). The binding of cyclosporine to calcineurin results in significant immunosuppression.
  • cyclosporine analogs modified at amino acid-1 e.g., "ISATX247", "ISA247”, or "ISA” are disclosed in WO 1999/018120 and WO 2003/033527, which are incorporated herein by reference in their entirety.
  • ISA247 is structurally identical to CsA and exhibits enhanced immunosuppression and reduced toxicity over many other cyclosporines.
  • HBx is a multifunctional viral protein known to be essential for HBV replication and for the maintenance and progression of chronic HBV disease. HBx is involved in the production and secretion of key viral proteins, such as HBsAg and HBeAg. HBx further disables host factors that restrict the production of HBV and other viral products, including covalently closed circular DNA (cccDNA), which is key to the persistence of chronic HBV infection. (HBsAg) is another key HBV protein. High levels of HBsAg in HBV-infected patients is a predictor for progression of disease, including liver fibrosis, cirrhosis, and cancer.
  • CyPs are involved in a multitude of cellular processes. Recent studies show that CyPs may represent additional drug targets for hepatitis B treatment. Accordingly, cyclosporines that bind to CyPs can be useful in the treatment of many disease indications, such as heptatitis B.
  • the concomitant effects of immunosuppression limit the utility of cyclosporines in clinical practice. Only a few CsA analogs have been proven to have little or reduced immunosuppressive activity and still retain their ability to bind CyPs. Those CsA analogs generally require laborious and complex modification of amino acids 3 and 4 that involves disruption of the cyclosporine ring structure. Also, a single modification of amino acid 1 results in increased immunosuppression.
  • the present application relates to a method of treating and/or preventing a hepatitis B (HBV) disease, comprising administering to a subject in need thereof a compound of
  • R', Rl, R2, and R23 are each as defined herein below.
  • the present application relates to a method of treating and/or preventing a HBV disease, comprising administering Compound I, or a pharmaceutically acceptable salt thereof, to a subject in need thereof:
  • R' is H:
  • R23 is methyl
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in treating and/or preventing a HBV disease in a subject in need thereof.
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treatment and/or prevention of a FIBV disease in a subject in need thereof.
  • the present application also relates to use of a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment and/or prevention of a FIBV disease in a subject in need thereof.
  • the present application relates to a method of treating and/or preventing a FIBV disease, comprising administering to a subject in need thereof a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, in combination with a second therapeutic agent.
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in treating and/or preventing a HBV disease in a subject in need thereof, wherein the subject is also administered a second therapeutic agent.
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered a second therapeutic agent.
  • the present application also relates to use of a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered a second therapeutic agent.
  • the present application relates to treating/treatment of a HBV disease in a subject in need thereof.
  • the present application relates to
  • the treatment and/or prevention of a HBV disease is through modulation (e.g., inhibition) of an interaction of HBV X protein (HBx) with cyclophilin A (CypA).
  • the treatment and/or prevention of a HBV disease is through modulation (e.g., inhibition) of an interaction of Hepatitis B surface antigen (HBsAg) with cyclophilin A (CypA).
  • the present application relates to a method of modulating (e.g., inhibiting) an interaction of HBx with CypA, comprising administering to a subject in need thereof a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof.
  • the present application also relates to a method of modulating (e.g., inhibiting) an interaction of HBsAg with CypA, comprising administering to a subject in need thereof a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof).
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in modulating (e.g., inhibiting) an interaction of HBx with CypA in a subject in need thereof.
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in modulating (e.g., inhibiting) an interaction of HBsAg with CypA in a subject in need thereof.
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for modulation (e.g., inhibition) of an interaction of HBx with CypA in a subject in need thereof.
  • the present application also relates to a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for modulation (e.g., inhibition) of an interaction of HBsAg with CypA in a subject in need thereof.
  • the present application also relates to use of a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for modulation (e.g., inhibition) of an interaction of HBx with CypA in a subject in need thereof.
  • the present application also relates to use of a compound of Formula L or Compound I, or a
  • Figure 1A illustrates a GST pulldown assay which measures the inhibition of interaction of HBx with CypA by a compound of the present application.
  • Figure IB is a Western blot showing inhibition of interaction of HBx with CypA by a compound of the present application at the indicated concentrations.
  • Figure 2A is a chart displaying inhibition of interaction of HBx with CypA as a function of concentration of a compound of the present application, Compound II, or Alisporivir.
  • Figure 2B is a chart displaying inhibition of cyclophilin isomerase activity as a function of concentration of a compound of the present application, Alisporivir, or CsA.
  • Figure 3 illustrates a microtiter plate binding assay which measures the inhibition of interaction of HBx with CypA by a compound of the present application.
  • the present application relates to a method of treating and/or preventing a hepatitis B virus (HBV) disease, comprising administering to a subject in need thereof a compound of Formula L:
  • R' is H or acetyl
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain from 2 to 15 carbon atoms in length;
  • R2 is selected from the group consisting of:
  • xi a saturated or unsaturated straight or branched aliphatic carbon chain optionally containing a substituent selected from the group consisting of ketones, hydroxyls, nitriles, carboxylic acids, esters, 1,3-dioxolanes, halogens, and oxo;
  • xii an aromatic group containing a substituent selected from the group consisting of halides, esters and nitro;
  • xiii a combination of the saturated or unsaturated straight or branched aliphatic carbon chain of (xi) and the aromatic group of (xii);
  • R23 is a saturated or unsaturated straight or branched optionally substituted aliphatic carbon chain.
  • R1-R2 is selected from the group consisting
  • R2 is selected from the group consisting wherein:
  • R5 is a saturated or unsaturated straight or branched aliphatic carbon chain between 1 and 10 carbons in length
  • R6 is a monohydroxylated, dihydroxylated, trihydroxylated, or polyhydroxylated saturated or unsaturated straight or branched aliphatic carbon chain between 1 and 10 carbons in length.
  • R1-R2 comprises a saturated or unsaturated straight or branched aliphatic carbon chain of between 2 and 5 carbons optionally substituted with a substituent selected from the group consisting of ketones, hydroxyls, nitriles, halogens, oxo, carboxylic acids, esters, and 1,3-dioxolanes.
  • R23 is selected from the group consisting of:
  • R23 comprises an optionally substituted alkyl, including optionally substituted C1-C3 alkyl. Said alkyl may be substituted with amino and may comprise a C1-C3- Ala wherein said compound comprises the D-epimer. In one embodiment, R23 can be MeAla.
  • compounds of Formula I include the compounds wherein R' is H, Rl is an alkyl or alkenyl between 2 and 15 carbons (e.g., between 2 and 12 carbons, between 2 and 10 carbons, between 2 and 9 carbons, between 2 and 8 carbons, between 2 and 7 carbons, between 2 and 6 carbons, or between 2 and 6 carbons,) in length, and R2 is selected from:
  • N,N-di substituted amide wherein the substituents are independently selected from an alkyl between 1 and 7 carbons in length and a heterocyclic ring comprising 1-3 heteroatoms selected from O, N and S;
  • ketone wherein the carbonyl group of the ketone is connected to Rl and an alkyl or alkenyl chain between 1 and 7 carbons in length;
  • phenyl optionally substituted with one or more substituents independently selected from nitrogen dioxide, a fluorine, an amine, an ester, and a carboxyl group.
  • the present application relates to a method of treating and/or preventing a HBV disease, comprising administering to a subject in need thereof Compound I, or a pharmaceutically acceptable salt thereof:
  • R' is H
  • R23 is methyl.
  • a compound of Formula L or Compound I is a D-epimer, wherein the chiral center of the D-epimer is the carbon atom to which R23 is attached.
  • a compound of Formula L or Compound I is an L-epimer, wherein the chiral center of the L-epimer is the carbon atom to which R23 is attached.
  • a compound of Formula L or Compound I is a mixture of D-epimer and L-epimer, wherein the chiral center of the D-epimer and the L-epimer is the carbon atom to which R23 is attached.
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in treating and/or preventing a HBV disease in a subject in need thereof.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • use of a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof.
  • the treatment and/or prevention of a HBV disease is through modulation (e.g., inhibition) of an interaction of HBV X protein (HBx) with cyclophilin A (CypA).
  • the treatment and/or prevention of a HBV disease is through modulation (e.g., inhibition) of an interaction of Hepatitis B surface antigen (HBsAg) with cyclophilin A (CypA).
  • the present application relates to a method of modulating (e.g., inhibiting) an interaction of HBx with CypA, comprising administering to a subject in need thereof a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof).
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof.
  • the present application also relates to a method of modulating (e.g., inhibiting) an interaction of HBsAg with CypA, comprising administering to a subject in need thereof a compound of the application (e.g., a compound of Formula L or Compound I, or a
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in modulating (e.g., inhibiting) an interaction of HBx with CypA in a subject in need thereof.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application further relates to a compound of the application (e.g., a compound of
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in the manufacture of a medicament for modulation (e.g., inhibition) of an interaction of HBx with CypA in a subject in need thereof.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to use of a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for modulation (e.g., inhibition) of an interaction of HBx with CypA in a subject in need thereof.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application relates to a method of treating and/or preventing a HBV disease, comprising administering to a subject in need thereof a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof), in combination with a second therapeutic agent.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in treating and/or preventing a HBV disease in a subject in need thereof, wherein the subject is also administered a second therapeutic agent.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered a second therapeutic agent.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to use of a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered a second therapeutic agent.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the second therapeutic agent can be any agent that is effective in treating and/or preventing a HBV disease, alone or in combination with another therapeutic agent.
  • the second therapeutic agent is a small molecule agent (e.g., with a MW of less than 2,000 Dalton, 1,000 Dalton, or 500 Dalton).
  • the second therapeutic agent is Compound II:
  • the present application relates to a method of treating and/or preventing a HBV disease, comprising administering to a subject in need thereof a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof), in combination with Compound II, or a pharmaceutically acceptable salt thereof.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application relates to a method of treating and/or preventing a HBV disease, comprising administering to a subject in need thereof Compound I or a pharmaceutically acceptable salt thereof, in combination with Compound II or a pharmaceutically acceptable salt thereof.
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in treating and/or preventing a HBV disease in a subject in need thereof, wherein the subject is also administered Compound II.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to Compound I or a
  • the present application also relates to a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) for use in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered Compound II.
  • a compound of the application e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof
  • the present application also relates to Compound I or a pharmaceutically acceptable salt thereof for use in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered Compound II or a pharmaceutically acceptable salt thereof.
  • the present application also relates to use of a compound of the application (e.g., a compound of Formula L or Compound I, or a pharmaceutically acceptable salt thereof) in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered Compound II.
  • the present application also relates to use of Compound I or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treatment and/or prevention of a HBV disease in a subject in need thereof, wherein the subject is also administered Compound II or a pharmaceutically acceptable salt thereof.
  • the present application relates to treating a HBV disease in a subject in need thereof.
  • the present application relates to preventing a HBV disease in a subject in need thereof.
  • a HBV disease is a disease or condition caused by or associated with HBV infection.
  • a HBV disease includes hepatitis B, cirrhosis, and hepatocellular carcinoma.
  • a HBV disease is hepatitis B.
  • a HBV disease is mediated by an interaction of CypA with HBx. In one embodiment, a HBV disease is mediated by an interaction of CypA with HBsAg. In one embodiment, a HBV disease is mediated by an interaction of CypA with HBx or HBsAg. In one embodiment, a HBV disease is mediated by an interaction of CypA with HBx and HBsAg. A HBV disease is mediated by an interaction of CypA with HBx and/or HBsAg when an interaction of CypA with HBx and/or HBsAg plays a certain role in the initiation, development, progression, persistence, and/or manifestation of the HBV disease. In one embodiment, a HBV disease mediated by an interaction of CypA with HBx and/or HBsAg is different from a HBV disease not mediated by an interaction of CypA with HBx and/or HBsAg
  • HBx is a hepatitis B viral protein that is 154 amino acids long and interferes with transcription, signal transduction, cell cycle progress, protein degradation, apoptosis and chromosomal stability in the host.
  • HBsAg is the surface antigen of the hepatitis B virus (HBV). It indicates a current hepatitis B infection.
  • Carboxylic acid has the formula COOH, but may include a group in which the carboxyl moiety is connected to one of the following groups:
  • alkyl which may be substituted (for example, alkyl of 2 to 15 carbons);
  • alkenyl which may be substituted (for example, alkenyl of 2 to 15 carbons);
  • alkynyl which may be substituted (for example, alkynyl of 2 to 15 carbons).
  • the substituents as described herein may include halogen (for example, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxy, thiol which may be substituted (for example, thiol, C1-C4 alkylthio, etc.), amino which may be substituted (for example, amino, mono-Cl-C4 alkylamino, di-Cl-C4 alkylamino, 5- to 6-membered cyclic amino such as tetrahydropyrrole, piperazine, piped dine, morpholine, thiomorpholine, pyrrole, imidazole, etc.), C1-C4 alkoxy which may be halogenated (for example, methoxy, ethoxy, propoxy, butoxy, trifluoromethoxy, trifluoroethoxy, etc.), C1-C4 alkoxy-Cl-C4 alkoxy which may be halogenated (for example, methoxy
  • substituents of the above "amino which may be substituted” may bind each other to form a cyclic amino group (for example, a group which is formed by subtracting a hydrogen atom from the ring constituting nitrogen atom of a 5- to 6-membered ring such as tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, imidazole, etc. so that a substituent can be attached to the nitrogen atom, or the like).
  • a cyclic amino group for example, a group which is formed by subtracting a hydrogen atom from the ring constituting nitrogen atom of a 5- to 6-membered ring such as tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, imidazole, etc.
  • the cyclic amino group may be substituted and examples of the substituent include halogen (for example, fluorine, chlorine, bromine, iodine, etc.), nitro, cyano, hydroxy, thiol which may be substituted (for example, thiol, C1-C4 alkylthio, etc.), amino which may be substituted (for example, amino, mono-Cl-C4 alkylamino, di-Cl-C4 alkylamino, 5- to 6-membered cyclic amino such as tetrahydropyrrole, piperazine, piperidine, morpholine, thiomorpholine, pyrrole, imidazole, etc.), carboxyl which may be esterified or amidated (for example, carboxyl, C1-C4 alkoxy-carbonyl, carbamoyl, mono- C1-C4 alkyl-carbamoyl, di-Cl-C4 alkyl-carbamoyl, etc.
  • “Amine” includes a group which may be unsubstituted or in which the amine moiety is N-substituted or N,N disubstituted having one or two substituents which may be independently selected from:
  • alkyl which may be substituted (for example, alkyl of 2 to 15 carbons);
  • alkenyl which may be substituted (for example, alkenyl of 2 to 15 carbons);
  • alkynyl which may be substituted (for example, alkynyl of 2 to 15 carbons); 4. formyl or acyl which may be substituted (for example, alkanoyl of 2 to 4 carbons (for example, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfonyl of 1 to 4 carbons (for example, methanesulfonyl, ethanesulfonyl, etc.), and the like);
  • aryl which may be substituted (for example, phenyl, naphthyl, etc.); and the like;
  • Amide includes a compound in which the carboxylic group of the amide moiety is connected to a substituent independently selected from the substituents as defined above ⁇ e.g., for "carboxylic acid”), connected to the amino group of the amide moiety is an N-substituted or N,N disubstituted having one or two substituents, respectively, which may be independently selected from:
  • alkyl which may be substituted (for example, alkyl of 2 to 15 carbons);
  • alkenyl which may be substituted (for example, alkenyl of 2 to 15 carbons);
  • alkynyl which may be substituted (for example, alkynyl of 2 to 15 carbons);
  • formyl or acyl which may be substituted for example, alkanoyl of 2 to 4 carbons (for example, acetyl, propionyl, butyryl, isobutyryl, etc.), alkylsulfonyl of 1 to 4 carbons (for example, methanesulfonyl, ethanesulfonyl, etc.) and the like);
  • aryl which may be substituted (for example, phenyl, naphthyl, etc.); and the like
  • Aryl may be exemplified by a monocyclic or fused polycyclic aromatic hydrocarbon group, and for example, a C6-C14 aryl group such as phenyl, naphthyl, anthryl, phenanthryl or acenaphthylenyl, and the like are preferred, with phenyl being preferred.
  • Said aryl may be substituted with one or more substituents, such as lower alkoxy ⁇ e.g., C1-C6 alkoxy such as methoxy, ethoxy or propoxy, etc.), a halogen atom ⁇ e.g., fluorine, chlorine, bromine, iodine, etc.), lower alkyl ⁇ e.g., C1-C6 alkyl such as methyl, ethyl or propyl, etc.), lower alkenyl ⁇ e.g., C2-C6 alkenyl such as vinyl or allyl, etc.), lower alkynyl ⁇ e.g., C2-C6 alkynyl such as ethynyl or propargyl, etc.), amino which may be substituted, hydroxyl which may be substituted, cyano, amidino which may be substituted, carboxyl, lower alkoxycarbonyl ⁇ e.g., C1-C6 alkoxycarbonyl such
  • Ketone includes a compound in which the carbonyl group of the ketone moiety is connected to one or two substituents independently selected from the substituents as defined above (e.g., for “carboxylic acid”).
  • Ester includes either a carboxylic or an alcohol ester wherein of the ester group is composed of one or two substituents independently selected from the substituents as defined above (e.g. , for "carboxylic acid” or for “aryl”).
  • Alkyl unless otherwise defined is an alkyl of 1 to 15 carbon units in length.
  • “alkyl” is an alkyl of 1 to 6 carbon units, 1 to 5 carbon units, 1 to 4 carbon units, or 1 to 3 carbon units (e.g., methyl, ethyl, propyl, i-propyl, butyl, i-butyl, s-butyl, t-butyl, pentyl, or hexyl).
  • Aromatic group may be exemplified by aryl as defined above, or a 5- to 6-membered aromatic monocyclic heterocyclic group such as furyl, thienyl, pyrrolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, imidazolyl, pyrazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,3,4- oxadiazolyl, furazanyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,3,4-thiadiazolyl, 1,2,3-triazolyl, 1,2,4-triazolyl, tetrazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl or the like; and a 8- to 16-membered (e.g., 10- to 12-membered) aromatic fuse
  • Non-immunosuppressive refers to the ability of a compound to exhibit a substantially reduced level of suppression of the immune system as compared with CsA, as measured by the compound's ability to inhibit the proliferation of human lymphocytes in cell culture, for example, as measured by the method set out in the Examples.
  • Analogue or “analog” means a structural analogue of CsA that differs from CsA in one or more functional groups. For example, such analogues preserve at least a substantial portion of the ability of CsA to bind CyP.
  • subject refers to a mammal.
  • a subject therefore refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, and the like.
  • the subject is a human.
  • the subject may be referred to herein as a patient.
  • Treat refer to a method of alleviating or abating a disease and/or its attendant symptoms.
  • preventing or “prevent” describes reducing or eliminating the onset of the symptoms or complications of the disease, condition or disorder.
  • terapéuticaally effective amount of a compound or pharmaceutical composition of the application means a sufficient amount of the compound or pharmaceutical composition so as to decrease the symptoms of a disorder in a subject.
  • composition of this application will be at a reasonable benefit/risk ratio applicable to any medical treatment. It will be understood, however, that the total daily usage of the compounds and compositions of the present application will be decided by the attending physician within the scope of sound medical judgment.
  • the specific inhibitory dose for any particular patient will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the patient; the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or coincidental with the specific compound employed; and like factors well known in the medical arts.
  • the term "pharmaceutically acceptable salt” refers to those salts of the compounds formed by the process of the present application which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.
  • Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J.
  • the salts can be prepared in situ during the final isolation and purification of the compounds of the application, or separately by reacting the free base or acid function with a suitable acid or base.
  • salts examples include, but are not limited to, nontoxic acid addition salts: salts formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid.
  • Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate,
  • benzenesulfonate benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate
  • alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like.
  • Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
  • the compounds of the present application may exist in the form of optically active compounds.
  • the present application contemplates all enantiomers of optically active compounds within the scope of the above formulae, both individually and in mixtures of racemates.
  • the present application includes prodrugs of the compounds defined herein.
  • Optical isomers may be prepared from their respective optically active precursors by the procedures described herein, or by resolving the racemic mixtures.
  • the resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 1981).
  • “Isomerism” means compounds that have identical molecular formulae but differ in the sequence of bonding of their atoms or in the arrangement of their atoms in space. Isomers that differ in the arrangement of their atoms in space are termed “stereoisomers”. Stereoisomers that are not mirror images of one another are termed “diastereoisomers”, and stereoisomers that are non-superimposable mirror images of each other are termed “enantiomers” or sometimes optical isomers. A mixture containing equal amounts of individual enantiomeric forms of opposite chirality is termed a "racemic mixture”.
  • a carbon atom bonded to four non-identical substituents is termed a "chiral center”.
  • Chiral isomer means a compound with at least one chiral center. Compounds with more than one chiral center may exist either as an individual diastereomer or as a mixture of diastereomers, termed "diastereomeric mixture". When one chiral center is present, a stereoisomer may be characterized by the absolute configuration (R or S) of that chiral center. Absolute configuration refers to the arrangement in space of the substituents attached to the chiral center. The substituents attached to the chiral center under consideration are ranked in accordance with the Sequence Rule of Cahn, Ingold and Prelog. (Cahn et al., Angew. Chem. Inter. Edit.
  • Epimer means one member of a pair of stereoisomers wherein the two isomers differ in configuration at only one stereogenic center and all other stereocenters in the molecules, if any, are the same in each.
  • “Geometric isomer” means the diastereomers that owe their existence to hindered rotation about double bonds. These configurations are differentiated in their names by the prefixes cis and trans, or Z and E, which indicate that the groups are on the same or opposite side of the double bond in the molecule according to the Cahn-Ingold-Prelog rules.
  • atropic isomers are a type of stereoisomer in which the atoms of two isomers are arranged differently in space. Atropic isomers owe their existence to a restricted rotation caused by hindrance of rotation of large groups about a central bond. Such atropic isomers typically exist as a mixture, however as a result of recent advances in chromatography techniques; it has been possible to separate mixtures of two atropic isomers in select cases.
  • Tautomer is one of two or more structural isomers that exist in equilibrium and is readily converted from one isomeric form to another. This conversion results in the formal migration of a hydrogen atom accompanied by a switch of adjacent conjugated double bonds. Tautomers exist as a mixture of a tautomeric set in solution. In solid form, usually one tautomer predominates. In solutions where tautomerization is possible, a chemical equilibrium of the tautomers will be reached. The exact ratio of the tautomers depends on several factors, including temperature, solvent and pH. The concept of tautomers that are interconvertible by tautomerizations is called tautomensm.
  • keto-enol tautomensm a simultaneous shift of electrons and a hydrogen atom occurs.
  • Ring-chain tautomerism arises as a result of the aldehyde group (-CHO) in a sugar chain molecule reacting with one of the hydroxy groups (-OH) in the same molecule to give it a cyclic (ring-shaped) form as exhibited by glucose.
  • tautomeric pairs are: ketone-enol, amide-nitrile, lactam- lactim, amide-imidic acid tautomerism in heterocyclic rings (e.g., in nucleobases such as guanine, thymine and cytosine), amine-enamine and enamine-enamine.
  • the compounds of this application may also be represented in multiple tautomeric forms, in such instances, the application expressly includes all tautomeric forms of the compounds described herein (e.g., alkylation of a ring system may result in alkylation at multiple sites, the application expressly includes all such reaction products).
  • the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like.
  • the structural formula of the compound represents a certain isomer for convenience in some cases, but the present application includes all isomers, such as geometrical isomers, optical isomers based on an asymmetrical carbon, stereoisomers, tautomers, and the like.
  • a compound of this application may be administered neat or with a pharmaceutical earner to a warm-blooded animal in need thereof.
  • the pharmaceutical carrier may be solid or liquid.
  • the compound may be administered orally, topically,
  • parenterally by inhalation spray or rectally in dosage unit formulations containing conventional non-toxic pharmaceutically acceptable carriers, adjuvants and vehicles.
  • parenteral includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques.
  • compositions containing the inventive mixture may be in a form suitable for oral use, for example, as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard or soft capsules, or syrups or elixirs.
  • compositions intended for oral use may be prepared according to methods known to the art for the manufacture of pharmaceutical compositions and such compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparation.
  • excipients may also be manufactured by known methods.
  • the excipients used may be for example, (1) inert diluents such as calcium carbonate, lactose, calcium phosphate or sodium phosphate; (2) granulating and disintegrating agents such as corn starch, or alginic acid; (3) binding agents such as starch, gelatin or acacia, and (4) lubricating agents such as magnesium stearate, stearic acid or talc.
  • the tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
  • a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated by the techniques described in the U.S. Patent Number 4,256, 108; 4, 160,452; and 4,265,874 to form osmotic therapeutic tablets for controlled release.
  • formulations for oral use may be in the form of hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin. They may also be in the form of soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.
  • an inert solid diluent for example, calcium carbonate, calcium phosphate or kaolin.
  • water or an oil medium for example peanut oil, liquid paraffin, or olive oil.
  • Aqueous suspensions normally contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions.
  • excipients may include: (1) suspending agents such as sodium carboxymethylcellulose, methylcellulose,
  • dispersing or wetting agents which may be a naturally-occurring phosphatide such as lecithin, a condensation product of an alkylene oxide with a fatty acid, for example, polyoxyethylene stearate, a condensation product of ethylene oxide with a long chain aliphatic alcohol, for example, heptadecaethyleneoxycetanol, a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol such as polyoxyethylene sorbitol monooleate, or a condensation product of ethylene oxide with a partial ester derived from a fatty acid and a hexitol anhydride, for example polyoxyethylene sorbitan monooleate.
  • a naturally-occurring phosphatide such as lecithin
  • a condensation product of an alkylene oxide with a fatty acid for example, polyoxyethylene stearate
  • a condensation product of ethylene oxide with a long chain aliphatic alcohol for example
  • the aqueous suspensions may also contain one or more preservatives, for example, ethyl or n-propyl p-hydroxybenzoate; one or more coloring agents; one or more flavoring agents; and one or more sweetening agents such as sucrose, aspartame or saccharin.
  • preservatives for example, ethyl or n-propyl p-hydroxybenzoate
  • coloring agents for example, ethyl or n-propyl p-hydroxybenzoate
  • flavoring agents for example, ethyl or n-propyl p-hydroxybenzoate
  • sweetening agents such as sucrose, aspartame or saccharin.
  • Oily suspension may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, a fish oil which contains omega 3 fatty acid, or in a mineral oil such as liquid paraffin.
  • the oily suspensions may contain a thickening agent, for example beeswax, hard paraffin or cetyl alcohol. Sweetening agents and flavoring agents may be added to provide a palatable oral preparation. These compositions may be preserved by the addition of an antioxidant such as ascorbic acid.
  • Dispersible powders and granules are suitable for the preparation of an aqueous suspension. They provide the active ingredient in a mixture with a dispersing or wetting agent, a suspending agent and one or more preservatives. Suitable dispersing or wetting agents and suspending agents are exemplified by those already mentioned above. Additional excipients, for example, those sweetening, flavoring and coloring agents described above may also be present.
  • the pharmaceutical compositions containing the inventive mixture may also be in the form of oil-in-water emulsions.
  • the oily phase may be a vegetable oil such as olive oil or arachis oils, or a mineral oil such as liquid paraffin or a mixture thereof.
  • Suitable emulsifying agents may be (1) naturally-occurring gums such as gum acacia and gum tragacanth, (2) naturally-occurring phosphatides such as soy bean and lecithin, (3) esters or partial ester 30 derived from fatty acids and hexitol anhydrides, for example, sorbitan monooleate, (4) condensation products of said partial esters with ethylene oxide, for example, polyoxyethylene sorbitan monooleate.
  • the emulsions may also contain sweetening and flavoring agents.
  • Syrups and elixirs may be formulated with sweetening agents, for example, glycerol, propylene glycol, sorbitol, aspartame or sucrose. Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
  • sweetening agents for example, glycerol, propylene glycol, sorbitol, aspartame or sucrose.
  • Such formulations may also contain a demulcent, a preservative, and flavoring and coloring agents.
  • the pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleagenous suspension.
  • This suspension may be formulated according to known methods using those suitable dispersing or wetting agents and suspending agents which have been mentioned above.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example as a solution in 1,3- butanediol.
  • the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or di-glycerides.
  • fatty acids such as oleic acid find use in the preparation of injectables.
  • the inventive compound may also be administered in the form of suppositories for rectal administration of the drug.
  • Suitable compositions can be prepared by mixing the compound with a suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • suitable non-irritating excipient which is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt in the rectum to release the drug.
  • Such materials are cocoa butter and polyethylene glycols.
  • suitable creams, ointments, jellies, solutions or suspensions, etc. which normally are used with cyclosporine may be employed.
  • a liquid solution containing a surfactant, ethanol, a lipophilic and/or an amphiphilic solvent as non-active ingredients is used.
  • an oral multiple emulsion formula containing the isomeric analogue mixture and the following non- medicinal ingredients: d-alpha Tocopheryl polyethylene glycol 1000 succinate (vitamin E TPGS), medium chain triglyceride (MCT) oil, Tween 40, and ethanol is used.
  • a soft gelatin capsule comprising gelatin, glycerin, water, and sorbitol) containing the compound and the same non-medicinal ingredients as the oral solution may also preferably be used.
  • X is a halide (including but not limited to CI, Br, and I), and RIO is a saturated or unsaturated straight or branched aliphatic carbon chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters, and 1,3- dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters and nitro; or a combination of the aforementioned saturated or unsaturated straight or branched aliphatic carbon chain and the aforementioned aromatic groups.
  • the Wittig reaction is broadly applicable to a wide range of substrates and reactants.
  • the side chain which is introduced to the substrate in the reaction, can represent any number of branched and unbranched, saturated and unsaturated aliphatic compounds of variable length (R') and may contain a broad range of functional groups.
  • a base such as potassium tert-butoxide (KOtBu) is used to generate an ylide from a phosphonium salt. The ylide reacts with the carbonyl group of the substrate, CsA-aldehyde, to form an alkene.
  • Phosphonium salts containing a carboxylic acid side chain require at least two equivalents of base to generate the ylide.
  • X is a halide (including but not limited to CI, Br, and I), and R12 is a saturated or unsaturated straight or branched aliphatic carbon chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters, and 1,3- dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters, and nitro; or a combination of the aforementioned saturated or unsaturated straight or branched aliphatic carbon chain and the aforementioned aromatic groups.
  • Reaction 3 the following compounds were synthesized. Synthesis of 404-20
  • R12 is a saturated or unsaturated straight or branched aliphatic carbon chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters, amides, acyl -protected amines, and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters, amines, and nitro; or a combination of the aforementioned saturated or unsaturated straight or branched aliphatic carbon chain and the aforementioned aromatic groups.
  • R12 is a saturated or unsaturated straight or branched aliphatic carbon chain, optionally containing a substituent selected from the group of ketones, hydroxyls, nitriles, carboxylic acids, esters, amides, acyl -protected amines, and 1,3-dioxolanes; an aromatic group, optionally containing a substituent selected from the group of halides, esters, amines and nitro; or a combination of the aforementioned saturated or unsaturated straight or branched aliphatic carbon chain and the aforementioned aromatic groups, and R' is H or acetyl.
  • acyl is any one of BOC, acetyl, or butyryl
  • acylating agent is any one of di-tert- butyldi carbonate, acetic anhydride, and butyric anhydride
  • Rl is a saturated or unsaturated straight or branched aliphatic group. It would be understood by one skilled in the art that the acylating agents described above may be replaced with a broad range of acylating agents to produce a similarly broad range of acyl-protected amines.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R' is H or acetyl
  • acyl is any one of BOC, acetyl or butyryl
  • acylating agent is any one of di-tert- butyldi carbonate, acetic anhydride, or butyric anhydride.
  • acylating agents including, dicarbonates, anhydrides and acyl halides can be employed to produce a broad range of acyl-protected amines, and Rl is a saturated or unsaturated straight or branched aliphatic group.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R15 and R16 are independently hydrogen or a saturated or unsaturated straight or branched aliphatic carbon chain, or R15R16 together forms a morpholinyl moiety.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R16 are independently hydrogen or a saturated or unsaturated straight or branched aliphatic carbon chain, or R15R16 together forms a morpholinyl moiety.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R17 is a saturated or unsaturated straight or branched aliphatic carbon chain, optionally containing a halogen or hydroxyl substituent.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R17 is a saturated or unsaturated straight or branched aliphatic carbon chain, optionally containing a halogen or hydroxyl substituent.
  • R' is a H or acetyl
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R20 is a saturated or unsaturated straight or branched aliphatic carbon chain.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R' is either a H or an acetyl group.
  • Rl is a saturated or unsaturated straight or branched aliphatic carbon chain
  • R23 is a saturated or unsaturated straight or branched aliphatic carbon chain
  • acetylated aldehyde (compound 3 in the example below), which is a suitable substrate for the modification of the 1- position via Wittig reaction.
  • This method allows introduction of residues to the AAl side-chain that have limited stability under the reaction conditions used in steps 1-3, such as strong base and oxidizing agents.
  • Synthesis is carried out according to Route A or B, respectively, as described above.
  • Step 2 Acetylation of the hydroxy-group on AAl side-chain
  • N,N-dimethylaminopyridine (19 mg, 0.15 mmol) and 20 mL anhydrous pyridine, followed by acetic anhydride (10 mL, 0.1 mol). The reaction is stirred at ambient temperature overnight.
  • Reaction substituents to the AA3 residue of compounds previously modified on the AA1 side-chain In addition to the groups available through Reaction 19, this route allows the introduction of substituents at AA3 that are unstable under the reaction conditions used in Reaction 20, e.g., a thiomethyl residue could undergo oxidation during the formation of the aldehyde in step 3 of this method.
  • a peptide substrate that includes a nitroanilide moiety was supplied to a reaction mixture containing CyP-A, test compound (CsA analog, CsA, or dimethylsulfoxide vehicle), and a second enzyme, alpha-chymotrypsin.
  • test compound CsA analog, CsA, or dimethylsulfoxide vehicle
  • alpha-chymotrypsin a second enzyme
  • Each test compound was tested at 10 concentrations in triplicate or quadruplicate.
  • the peptide was converted from the cis conformation to the trans conformation both by non-catalytic and CyP catalytic processes.
  • the trans isomer of the peptide, but not the cis isomer is a substrate for alpha-chymotrypsin.
  • Alpha-chymotrypsin immediately cleaved nitroanilide from the rest of the peptide, and free nitroanilide accumulated at a rate proportional to cis-trans isomerization. Since free nitroanilide is a colored product, its accumulation was quantified by measuring its absorbance with a spectrophotometer.
  • Nitroanilide accumulation was measured for 6 minutes, and first order rate constants for each reaction were calculated using Graphpad Prism software.
  • the CyP -A catalytic rate constant of each reaction was determined by subtracting the non-catalytic rate constant (derived from the reaction without CyP-A) from the total reaction rate constant. Plots of the catalytic rate constants as a function of inhibitor concentrations demonstrated the compounds' potencies, defined by their IC50 values.
  • the assay peptide was N-succinyl-alanine-alanine-proline-phenylalanine-p-nitroanilide. It was dissolved to a concentration of 3 mM in a solution of trifluoroethanolamine and lithium chloride (TFE/LiCl). TFE/LiCl was prepared fresh each day by dissolving lithium chloride in trifluoroethanolamine to a concentration of 17 mg/ml. Following dissolution of LiCl, the water content of the TFE/LiCl solution was reduced by adding heat-dried molecular sieves and gentle mixing the solution for at least 30 minutes.
  • the peptide was then dissolved in TFE/LiCl, and the solution cooled to 4°C - 8°C prior to the assays. Dissolution of the peptide in dry TFE/LiCl promoted more peptide to exist in the cis conformation at the beginning of each assay reaction. Data analysis showed that approximately 60% of the peptide in our assays began as a cis isomer which is consistent with reported data in the scientific literature. In the enzyme reactions the peptide was diluted 20-fold to a final assay concentration of 150 ⁇ .
  • test compounds consisted of CsA, CsA analogs, or dimethylsulfoxide (DMSO).
  • the starting solution (saline buffer) for the reaction buffer consisted of Hepes 50 mM, sodium chloride 100 mM, and human serum albumin 1 mg/ml, adjusted to pH 8.0 with sodium hydroxide.
  • the saline buffer was stored at 4°C when not in use.
  • bovine alpha-chymotrypsin was dissolved in a volume of saline buffer to a concentration of 1 mg/ml.
  • An aliquot of the alpha-chymotrypsin solution was removed to serve as the noncatalytic control reaction buffer.
  • Recombinant human CyP-A was added to the remainder of the chymotrypsin solution to a concentration of 5 nM.
  • the solution containing alpha-chymotrypsin and CyP-A was designated the reaction buffer and was used for preparation of the reaction solutions.
  • reactions were begun by dispensing 95 ⁇ of reaction buffer into each peptide-containing well using a 12- channel pipettor and mixing each reaction thoroughly by repeat pipetting to ensure uniform dissolution of the peptide.
  • the 12 reactions in each assay run were represented by the following: a) 10 reactions, representing one replicate for each of the 10 concentrations of one test
  • the raw data consisted of a time-dependent increase in OD405.
  • the peptide was completely converted to the trans isomer within approximately 150 seconds as demonstrated by a plateau in the OD405.
  • OD405 vs. time data were plotted with Graphpad Prism software and fitted with a one phase exponential equation to derive a first order rate constant K for each reaction.
  • the rate constant In reactions without CyP-A, the rate constant entirely represented the spontaneous noncatalytic, thermal cis-to-trans isomerization of the peptide and was defined as the noncatalytic rate constant Ko.
  • isomerization occurred both through noncatalytic and enzyme-catalyzed processes.
  • the rate constant K in CyP-A-containing reactions represented the sum of the noncatalytic rate constant Ko and the catalytic rate constant K ca t.
  • K ca t was calculated by subtracting Ko (obtained from the reaction without CyP-A) from the total rate constant K.
  • Kcat typically was 3 -fold higher than Ko in reactions with 5 nM CyP-A, 150 ⁇ peptide substrate, and no inhibitor.
  • a GST pulldown assay was conducted to measure the inhibition of interaction of HBx with CypA by a compound of the present application.
  • the assay is illustrated in Figure 1 A.
  • Figure IB a compound of the present application inhibited the interaction of HBx with CypA.
  • a microtiter plate binding assay was conducted to measure the inhibition of interaction of
  • HBx with CypA by a compound of the present application, as follows. 1. Bind anti-GST antibody to plate.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une méthode de traitement et/ou de prévention d'une maladie du virus de l'hépatite B (VHB) par l'inhibition de l'interaction de CypA avec la protéine X du VHB (HBx) et/ou un antigène de surface de l'hépatite B (HBags), comprenant l'administration, à un sujet qui en a besoin, d'un composé de formule L.
PCT/US2017/065132 2016-12-08 2017-12-07 Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3 WO2018106928A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662431746P 2016-12-08 2016-12-08
US62/431,746 2016-12-08
US201762479683P 2017-03-31 2017-03-31
US62/479,683 2017-03-31

Publications (1)

Publication Number Publication Date
WO2018106928A1 true WO2018106928A1 (fr) 2018-06-14

Family

ID=61006309

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2017/065132 WO2018106928A1 (fr) 2016-12-08 2017-12-07 Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3

Country Status (1)

Country Link
WO (1) WO2018106928A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168161A1 (fr) * 2020-02-19 2021-08-26 Hepion Pharmaceuticals, Inc. Utilisation d'analogues de cyclosporine pour le traitement de la fibrose
WO2021173723A1 (fr) * 2020-02-25 2021-09-02 Hepion Pharmaceuticals, Inc. Utilisation d'analogues de cyclosporine pour le traitement du cancer
WO2023219360A1 (fr) * 2022-05-09 2023-11-16 광주과학기술원 Composition pharmaceutique pour la prévention ou le traitement de l'hépatite b
WO2023247937A1 (fr) * 2022-06-21 2023-12-28 Ucl Business Ltd Analogues de cyclosporine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1999018120A1 (fr) 1997-10-08 1999-04-15 Isotechnika Inc. Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs
WO2003033527A2 (fr) 2001-10-19 2003-04-24 Isotechnika Inc. Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
WO2012079172A1 (fr) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4160452A (en) 1977-04-07 1979-07-10 Alza Corporation Osmotic system having laminated wall comprising semipermeable lamina and microporous lamina
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
WO1999018120A1 (fr) 1997-10-08 1999-04-15 Isotechnika Inc. Analogues de cyclosporine deuteres et leur utilisation comme immunomodulateurs
WO2003033527A2 (fr) 2001-10-19 2003-04-24 Isotechnika Inc. Melanges d'analogues de cyclosporine et leur utilisation comme agents immunomodulateurs
WO2012079172A1 (fr) 2010-12-15 2012-06-21 Isotechnika Pharma Inc. Molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
ANONYMOUS: "ContraVir's Cyclophilin Inhibitor CRV431 Potently Inhibits Essential Pathway in Hepatitis B", 8 December 2016 (2016-12-08), XP055460865, Retrieved from the Internet <URL:http://ir.contravir.com/news-releases/news-release-details/contravirs-cyclophilin-inhibitor-crv431-potently-inhibits> [retrieved on 20180320] *
ANONYMOUS: "CRV431", 1 May 2016 (2016-05-01), XP055460890, Retrieved from the Internet <URL:http://drugprofiles.informa.com/drug_profiles/29606-crv431> [retrieved on 20180320] *
CAHN ET AL., ANGEW. CHEM. INTER. EDIT., vol. 5, 1966, pages 385
CAHN ET AL., ANGEW. CHEM., vol. 78, 1966, pages 413
CAHN ET AL., EXPERIENTIA, vol. 12, 1956, pages 81
CAHN, J. CHEM. EDUC., vol. 41, 1964, pages 116
CAHN; INGOLD, J. CHEM. SOC., 1951, pages 612
FOSTER R T ET AL: "CRV431 and CMX157: anti-HBV combination effects in vitro between a cyclophilin inhibitor and a nucleotide prodrug", JOURNAL OF HEPATOLOGY, vol. 66, no. 1, 2017, XP085013003, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(17)31874-3 *
GALLAY P ET AL: "P0890 : Novel cyclophilin inhibitor CPI-431-32 shows broad spectrum antiviral activity by blocking replication of HCV, HBV and HIV-1 viruses", JOURNAL OF HEPATOLOGY, vol. 62, 2015, XP029162239, ISSN: 0168-8278, DOI: 10.1016/S0168-8278(15)31093-X *
JACQUES ET AL.: "Enantiomers, Racemates, and Resolutions", 1981, JOHN WILEY & SONS
JULES LEVIN: "CPI-431-32, A Novel Cyclophilin Inhibitor for Treatment of Chronic Hepatitis B: A Story of Clinical Utility", THE INTERNATIONAL LIVER CONGRESS(TM), 17 April 2016 (2016-04-17), XP055460841, Retrieved from the Internet <URL:http://www.natap.org/2016/EASL/EASL_133.htm> [retrieved on 20180320] *
PAINTER G R ET AL: "Evaluation of hexadecyloxypropyl-9-R-[2-(phosphonomethoxy)propyl]-adenine, CMX157, as a potential treatment for human immunodeficiency virus type 1 and hepatitis B virus infections", ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, AMERICAN SOCIETY FOR MICROBIOLOGY, vol. 51, no. 10, 1 October 2007 (2007-10-01), pages 3505 - 3509, XP002485783, ISSN: 0066-4804, DOI: 10.1128/AAC.00460-07 *
PHILIPPE A. GALLAY ET AL: "Characterization of the Anti-HCV Activities of the New Cyclophilin Inhibitor STG-175", PLOS ONE, vol. 11, no. 4, 22 April 2016 (2016-04-22), pages e0152036, XP055460521, DOI: 10.1371/journal.pone.0152036 *
ROBERT FOSTER ET AL: "CRV431: An Optimized Cyclophilin Inhibitor with Multiple Anti-HBV Activities, High Selectivity Index, and Synergy with CMX157", AASLD-EASL HBV TREATMENT ENDPOINTS WORKSHOP: FROM DISCOVERY TO REGULATORY APPROVAL, 9 September 2016 (2016-09-09), XP055460893, Retrieved from the Internet <URL:http://1zpkyu38mbmzo6c6947efbfe-wpengine.netdna-ssl.com/wp-content/uploads/2016/09/AASLD-Endpoints-Workshop-Aug-22-2016.pdf> [retrieved on 20180320] *
S. M. BERGE ET AL.: "pharmaceutically acceptable salts", J. PHARMACEUTICAL SCIENCES, vol. 66, 1977, pages 1 - 19
X. TIAN ET AL: "Hepatitis B Virus (HBV) Surface Antigen Interacts with and Promotes Cyclophilin A Secretion: Possible Link to Pathogenesis of HBV Infection", JOURNAL OF VIROLOGY., vol. 84, no. 7, 1 April 2010 (2010-04-01), US, pages 3373 - 3381, XP055460737, ISSN: 0022-538X, DOI: 10.1128/JVI.02555-09 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021168161A1 (fr) * 2020-02-19 2021-08-26 Hepion Pharmaceuticals, Inc. Utilisation d'analogues de cyclosporine pour le traitement de la fibrose
WO2021173723A1 (fr) * 2020-02-25 2021-09-02 Hepion Pharmaceuticals, Inc. Utilisation d'analogues de cyclosporine pour le traitement du cancer
CN115484961A (zh) * 2020-02-25 2022-12-16 海必恩制药公司 环孢菌素类似物用于治疗癌症的用途
WO2023219360A1 (fr) * 2022-05-09 2023-11-16 광주과학기술원 Composition pharmaceutique pour la prévention ou le traitement de l'hépatite b
WO2023247937A1 (fr) * 2022-06-21 2023-12-28 Ucl Business Ltd Analogues de cyclosporine

Similar Documents

Publication Publication Date Title
JP6144627B2 (ja) アミノ酸１および３で修飾されたシクロスポリン類似体分子
WO2018106928A1 (fr) Traitement et prévention de maladies du vhb par des molécules analogues de cyclosporine modifiées au niveau des acides aminés 1 et 3
JP5976322B2 (ja) テトラヒドロ−イミダゾ［１，５−ａ］ピラジン誘導体塩、その製造方法及び医薬用途
JP2015061853A (ja) ネクロトーシスの小分子阻害剤
EA026114B1 (ru) Макроциклические ингибиторы вирусов flaviviridae
KR20060073584A (ko) 아미노산 프로드럭
JP2014505035A5 (fr)
JP2012519193A5 (fr)
US20180296588A1 (en) Combination therapy for treating viral infections
JPH0471073B2 (fr)
WO2021011592A1 (fr) Composés en tant qu&#39;inhibiteurs d&#39;inflammasome de nlrp3 et compositions et utilisations de ceux-ci
JP2020515527A (ja) 置換イミダゾール塩系化合物、その調製方法、医薬組成物およびその応用
CA2629738C (fr) Nouveaux derives d&#39;indolizine, leur procede de preparation et les compositions therapeutiques les comprenant
HU199785B (en) Process for producing pyrrolidine-2-(1,3-dicarbonyl) derivatives and pharmaceutical compositions comprising same as active ingredient
JP4310191B2 (ja) タキサン誘導体結晶およびその製造方法
ES2949701T3 (es) Compuestos similares al 17beta-heterociclil-digitalis para el tratamiento de la insuficiencia cardíaca
US7230021B2 (en) Potent, simplified derivatives of pateamine A
JPS6232170B2 (fr)
EP3543238B1 (fr) Dérivés nucléosidiques ayant une activité antivirale
WO2016034634A1 (fr) Derives de n-aryl-2-amino-4-aryl-pyrimidines polyethers macrocycliques comme inhibiteurs de la ftl3 and jak
KR102437095B1 (ko) 캐스파제 저해제의 프로드럭
JP2004137185A (ja) チオフェン骨格を有する抗菌剤
EP1993555B1 (fr) Composition contenant des derives d&#39;amidine ou de carboxamide et des steroides a titre de medicament
EP1246824B1 (fr) Derives de diazepine carboxamide, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et leur utilisation
WO2024056798A1 (fr) Modulateurs du cftr macrocycliques

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17832393

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17832393

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载